TEMOZOLOMIDE - A NEW ORAL CYTOTOXIC CHEMOTHERAPEUTIC AGENT WITH PROMISING ACTIVITY AGAINST PRIMARY BRAIN-TUMORS
TEMOZOLOMIDE - A NEW ORAL CYTOTOXIC CHEMOTHERAPEUTIC AGENT WITH PROMISING ACTIVITY AGAINST PRIMARY BRAIN-TUMORS
复制标题
DOI：
10.1016/s0959-8049(05)80198-4
复制
发表时间：
1993-01-01
影响因子：
8.4
通讯作者：
STEVENS, MFG
中科院分区：
文献类型：
--
作者：
OREILLY, SM;NEWLANDS, ES;STEVENS, MFG
替莫唑胺是一种新的口服细胞毒性药物，已对28例原发性脑肿瘤患者进行了治疗。治疗剂量为150mg /M2/天，连续5天（即总剂量为750mg /M2），如果在第22天没有发现明显的骨髓抑制，则逐渐增加到200mg /M2/天，连续5天（即总剂量为1000mg /M2），随后每4周进行一次疗程。5/10放射治疗后复发的星形细胞瘤患者的计算机断层扫描（CT）有重大改善，另外1例患者的CT扫描有重大改善。在放疗前给予替莫唑胺2-3个疗程的新诊断的高级别星形细胞瘤患者中，有4/7观察到CT病变大小缩小。1例复发髓母细胞瘤在骨转移中有临床反应。替莫唑胺耐受性好，主观毒性小，通常可预测骨髓抑制，是治疗原发性脑肿瘤的一种有前景的新药。
Temozolomide, a new oral cytotoxic agent, has been given to 28 patients with primary brain tumours. Treatment was given at a dose of 150 Mg/M2/day for 5 days (i.e. total dose 750 mg/m2) escalating, if no significant myelosuppression was noted on day 22, to 200 mg/M2/day for 5 days (i.e. total dose 1000 mg/m2) for subsequent courses at 4 week intervals. A major improvement in computer tomography (CT) scan was noted in 5/10 patients with astrocytomas recurrent after radiotherapy, with a major clinical improvement but minor improvement on CT scan in one further patient. Reduction in the size of the CT lesion was also observed in 4/7 patients with newly diagnosed high grade astrocytomas given 2-3 courses of temozolomide prior to irradiation. 1 patient with recurrent medulloblastoma had a clinical response in bone metastases. Temozolomide was well tolerated with little subjective toxicity and usually predictable myelosuppression and is a promising new drug in the treatment of primary brain tumours.